bluebird bio Upgraded to "Hold" by Zacks (BLUE)

Share on StockTwits

bluebird bio (NASDAQ:BLUE) was upgraded by Zacks from a “sell” rating to a “hold” rating in a report released on Tuesday, Analyst Ratings Net reports.

According to Zacks, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. “

Several other brokerages have also recently commented on BLUE. Roth Capital reaffirmed a “buy” rating and set a $192.00 price target on shares of bluebird bio in a research note on Monday, July 13th. Wedbush reissued an “outperform” rating and issued a $222.00 target price on shares of bluebird bio in a research note on Thursday, June 18th. Piper Jaffray reaffirmed an “overweight” rating and set a $213.00 price target on shares of bluebird bio in a research report on Monday, June 15th. Vetr upgraded bluebird bio from a “hold” rating to a “strong-buy” rating and set a $183.56 price objective for the company in a report on Tuesday, July 7th. Finally, Cowen and Company restated an “outperform” rating on shares of bluebird bio in a research note on Monday, June 15th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. bluebird bio has an average rating of “Buy” and a consensus price target of $185.11.

Shares of bluebird bio (NASDAQ:BLUE) traded down 6.95% during trading on Tuesday, reaching $81.08. The company had a trading volume of 1,191,768 shares. bluebird bio has a 52-week low of $29.73 and a 52-week high of $197.35. The firm’s market capitalization is $2.94 billion. The company has a 50 day moving average of $116.30 and a 200-day moving average of $145.01.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Thursday, August 6th. The company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.79. The firm earned $4.94 million during the quarter, compared to the consensus estimate of $8.60 million. During the same quarter in the previous year, the firm earned ($0.06) EPS. The business’s revenue was down 22.1% on a year-over-year basis. Equities analysts expect that bluebird bio will post ($4.16) earnings per share for the current year.

In other bluebird bio news, CEO Nick Leschly sold 125,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $135.24, for a total value of $16,905,000.00. Following the sale, the chief executive officer now owns 246,521 shares in the company, valued at approximately $33,339,500.04. The transaction was disclosed in a filing with the Securities Exchange Commission, which is available at this link. Also, COO Jeffrey T. Walsh sold 11,000 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $130.02, for a total value of $1,430,220.00. The disclosure for this sale can be found here.

bluebird bio, Inc. is a clinical-stage biotechnology company. The Firm is focused on developing and commercializing products according to the transformative potential of gene therapy to treat patients with cancer and serious genetic diseases. The Company’s products contain Lenti-D, LentiGlobin and AUTO T Cells. The Organization is developing Lenti D to treat patients with CCALD (NASDAQ:BLUE), the acute type of ALD (Adrenoleukodystrophy). The Business is conducting a Phase II/III clinical study of Lenti-D in America. The Organization is developing LentiGlobin to treat patients with b-thalassemia and acute SCD (sickle cell disease). The Business is conducting a Phase I/II clinical study of LentiGlobin. It also began a second Phase I/II clinical study for LentiGlobin in Thailand, Australia and the United States. The Company is developing AUTO T cell technology to deliver T cells engineered to kill the cancer.

To get a free copy of the research report on bluebird bio (BLUE), click here. For more information about research offerings from Zacks Investment Research, visit

Receive News Ratings for bluebird bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for bluebird bio and related companies with’s FREE daily email newsletter.

<!– –>